Associate Professor Juliana Hamzah
- Vascular and metabolic disorders
- Inflammation, infectious disease and wounds
What do chronic inflammatory diseases have in common?
Can we develop new treatment solutions to treat chronic inflammatory diseases?
These are the clinically relevant questions Juliana is exploring in her research program. Juliana has over 13 years of research experience in developing strategies to specifically target chronic diseases such as cancer, atherosclerosis and tissue fibrosis for diagnostic imaging and local therapeutic interventions. Her research identifies cellular components in pathological tissues (such as blood vessels, inflammatory cells, and extracellular matrix) that can be specifically targeted with small peptide molecules. Using peptides for cell-specific delivery, her laboratory develops new therapeutic and theranostic agents for improved treatment efficacy and reduced toxicity.
As CHIRI’s Head of the Laboratory for Targeted Drug Delivery, Imaging and Therapy, Juliana provides cross-disciplinary research expertise that incorporates biomedical and biomaterial sciences. She has recently lead a development of a patented technology to specifically target matrix components in scar/fibrotic tissues for the delivery of anti-fibrotic agents.
Juliana is currently a Cancer Council WA Research Fellow. Earlier in her research career, Juliana was an American Heart Association Postdoctoral Fellow who trained internationally under the Program of Excellence in Nanotechnology. She returned to Perth in 2013 as R.D. Wright Biomedical Fellow funded by National Health and Medical Research Council and National Heart Foundation.
Juliana is based at the Harry Perkins Institute of Medical Research Office.